Lyell Immunopharma, Inc. Quarterly Operating Lease, Liability in USD from Q2 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Present value of lessee's discounted obligation for lease payments from operating lease.
Summary
Lyell Immunopharma, Inc. quarterly Operating Lease, Liability history and growth rate from Q2 2021 to Q3 2024.
  • Lyell Immunopharma, Inc. Operating Lease, Liability for the quarter ending September 30, 2024 was $58.6M, a 9.38% decline year-over-year.
Operating Lease, Liability, Quarterly (USD)
Operating Lease, Liability, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $58.6M -$6.06M -9.38% Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $60.2M -$5.85M -8.86% Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $61.8M -$4.81M -7.22% Mar 31, 2024 10-Q 2024-05-06
Q4 2023 $63.2M -$4.54M -6.7% Dec 31, 2023 10-K 2024-02-28
Q3 2023 $64.6M -$2.84M -4.21% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $66.1M -$1.48M -2.19% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $66.6M -$2.18M -3.17% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 $67.7M -$117K -0.17% Dec 31, 2022 10-K 2023-02-28
Q3 2022 $67.5M +$247K +0.37% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $67.6M +$4.1M +6.46% Jun 30, 2022 10-Q 2022-08-04
Q1 2022 $68.8M Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $67.8M Dec 31, 2021 10-K 2022-03-29
Q3 2021 $67.2M Sep 30, 2021 10-Q 2021-11-12
Q2 2021 $63.5M Jun 30, 2021 10-Q 2021-08-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.